Poster abstracts page 2008 meeting Marseille, France

НазваниеPoster abstracts page 2008 meeting Marseille, France
Размер0.81 Mb.
  1   2   3   4   5   6   7   8   9   ...   34
Poster abstracts PAGE 2008 meeting Marseille, France

Poster: Applications- Anti-infectives

caroline BAZZOLI Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation

helena colom Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus

ANNE DUBOIS Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy

Monika Frank Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns

María José García Sánchez Population Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis

Sylvain Goutelle A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin

Sylvain Goutelle Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study

FLORA MUSUAMBA-TSHINANU Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring

PARTHA NANDY Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection

Michael Neely Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children

Elisabet Nielsen Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study

Daniel Röshammar Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms

Catherine Mary Turner Sherwin Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates.

Nicolas Simon Population Pharmacokinetics of Atazanavir in HIV-infected Patients

Joel Tarning Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria

Jan-Stefan van der Walt Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring

Wei ZHAO Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients

Poster: Applications- Biologicals/vaccines

Daren Austin Use of mechanistic models to estimate target antigen load for monoclonal antibodies

Brigitte Lacroix Exposure-Response Modeling of the ACR20 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.

Brigitte Lacroix Exposure-response analysis of certolizumab pegol in Crohn’s disease population

Micha Levi Relationship Between Serum Concentration of the Interleukin-6 Receptor Inhibitor, Tocilizumab (TCZ), and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis

Etienne Pigeolet Granulocyte Colony Stimulating Factor Pharmacokinetics After Single and Repeated Administration of Several Doses.

David Ternant Development of anti-infliximab antibodies increases infliximab clearance in inflammatory bowel diseases

Justin Wilkins Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody

Poster: Applications- CNS

Aliénor Bergès Using VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions.

Chao Chen Population modeling of the relationship between ropinirole systemic exposure and efficacy in Parkinson’s disease

Rik de Greef Modeling and Simulation to Integrate Efficacy and Safety Data Following Full Development: a Case Study in Schizophrenia and Bipolar Disorder

Geraldine Ferron PK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect

Sophie Gisbert Analysing Raw Count data from an In Vitro Target Occupancy Assay to Select Doses for Human Safety/Tolerability Trial

Dymphy Huntjens PK/PD modeling of apomorphine-induced behaviour in macaques

Brigitte Lacroix Population Pharmacokinetics of Brivaracetam in Patients with Partial Epilepsy

Bart Laurijssens Model-Based Analysis of a Longitudinal Binary Response as the Primary Analysis for a Phase II Study in Migraine Prophylaxis.

Otilia Lillin-de Vries A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers.

IGOR LOCATELLI Population Pharmacokinetics of Risperidone in Patients with Acute Schizophrenia

Guangli Ma Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin

Sarah McLeay Scaling propofol doses for the obese: is lean body weight the answer?

Raymond Miller Exposure-Response Analysis of Longitudinal Adverse Event Data.

Gianluca Nucci A sparse sample PK & PKPD approach to estimate the time course of antipsychotic-induced D2 occupancy

Elba Romero Extended Link Model to Describe the Impact of Chronic Antiepileptic Therapy on the Effects of Neuromuscular Blocking Agents.

Monica Simeoni Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions.

Armel Stockis Levetiracetam exposure-response analysis in children with partial onset seizures

Katarina Vucicevic Estimation of Relative Bioavailability of Controlled-Release Carbamazepine Tablets Based on Routine TDM Data

Stefano Zamuner Mixed Effects Markov Models for Modelling Sleep in Insomniac Patients Treated with Placebo in a 28 Days Trial: Emphasis on the Break Points Selection

Poster: Applications- Coagulation

Xavier Delavenne Assessment of pharmacokinetic variability of fondaparinux in 809 patients treated after major orthopedic surgery: the POP-A-RIX study

Poster: Applications- CVS

Massimiliano Germani Nonparametric Modeling and Population Approach to the Individualized Heart Rate Correction of the QT Interval

Ihab Girgis Bayesian Modeling of QT Measurements: Focus on Baseline QTc

Carlos Hoyo-Vadillo Pharmacokinetics model for Nifedipine administered to Healthy Volunteers.

Kevin Krudys Bridging Cardiovascular Risk from Clinical Trials to Real Life Population

Poster: Applications- Endocrine

Paolo Denti Comparison of Different Population Analysis Approaches to the IVGTT Glucose Minimal Model

Silke Dittberner BI 1356 (proposed trade name ONDERO) pharmacokinetics and DPP-4 inhibition: Development of a target mediated PKPD model in type 2 diabetic patients

Silke Dittberner Target mediated drug disposition model for the DPP-4 inhibitor BI1356 (proposed trade name ONDERO): Is the structure identifiable?

Maria Garrido Simultaneous population pharmacodynamic modelling of the growth hormone and insulin-like growth factor-I effects after deep subcutaneous administration of Lanreotide Autogel® in acromegalic patients. Application of Nonparametric estimation method in NONMEM

Cyrus Ghobadi Pharmacokinetics of oral single-dose clomiphene citrate (CC) in polycystic ovary patient with anovulatory infertility

Tae Han Alteration of glucose and insulin regulatory networks for the treatment of type 2 diabetes mellitus

Nick Holford Delayed response to hypoglycaemic agents and effect on progression of type 2 diabetes

Petra Jauslin Identification of the Mechanism of Action of a Glucokinase Activator from OGTT Data in Type 2 Diabetics Using an Integrated Glucose-Insulin Model

Teun Post Disease System for osteoporosis: relating bone mineral density with measures of bone formation and resorption based on bone biology

Rujia Xie Model-Based Drug Development (MBDD) of Pegylated Growth Hormone (PEG-hGH) in the Treatment of Adult Growth Hormone Deficient (AGHD)

Rujia Xie Relationship between the Dose of Recombinant Human Growth Hormone (rhGH) and Insulin Growth Factor-1 (IGF-1) in Adult Patients with Growth Hormone Deficiency (AGHD)

Poster: Applications- Oncology

René Bruno Modeling and simulation to assess the use of change in tumor size as primary endpoint in Phase II studies in oncology

Francesca Del Bene Evaluating the Influence of Different Sources of Variability in the PK/PD Tumor Growth Inhibition (TGI) Model

Nicolas Frances Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination

Lena Friberg Scaling the Time-Course of Myelosuppression from Rats to Patients with a Semi-Physiological Model

Maria Garrido Biopharmaceutic and pharmacodynamic characterization of the in vitro anti-proliferative effect of new delivery systems of Cisplatin

Emma Hansson The Shape of the Myelosuppression Time-course is Related to the Probability of Developing Neutropenic Fever in Patients with Docetaxel-induced Grade IV Neutropenia

Emma Hansson Comparison of Inter-Occasion and Inter-Individual Variability in Chemotherapy- Induced Myelosuppression

Ron Keizer Population PK-PD modeling of E7820 and α2-integrin expression on platelets in patients with solid tumors and lymphomas

stijn Koolen Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer

Katharina Küster Matuzumab – Evaluation of the Population Pharmacokinetic Model and Analyses of the Covariate Impact on the Pharmacokinetic Profile

Andreas Lindauer Population Pharmacokinetics of High-dose Carboplatin

Antonin Schmitt External validation of a model based on cystatin C to predict carboplatin clearance

Elena Soto A semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the new PLK-1 inhibitor BI 2536 and its application in clinical development

Kellie Turner Reduced Folate Carrier Single Nucleotide Polymorphism Associated with Methotrexate Clearance in Breast Cancer Patients

Poster: Applications- Other topics

Corina Becker Whole-Body Physiologically-based Pharmacokinetic (WB-PBPK) Population Modelling to Simulate the Influence of Weight and Age on the Pharmacokinetics (PK) of a combined Oral Contraceptive Containing Drospirenone (DRSP) and Ethinylestradiol (EE)

Misba Beerahee Clinical Trial Simulation to Estimate the Sample Size for Investigation of the Impact of a Drug A on the Pharmacokinetics of Methotrexate, a common co-medication used in Rheumatoid Arthritis (RA)

Pascal Chanu Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class

Chao Chen Population PK/PD modelling of functional receptor occupancy in a first-time-in human study

Emmanuelle Comets Modelling is seldom used to describe pharmacokinetics in phase I clinical trials

Mike Dunlavey Simplified programming of population model user interfaces

Yumi Emoto Evaluation of Population PK/PD for Osteoporosis during a Vitamin D3 (1,25(OH)2D3) Derivative Therapy

Samuel Fanta Population Pharmacokinetics of Cyclosporine in Paediatric Renal Transplant Recipients

Dymphy Huntjens Receptor-mediated pharmacokinetic modeling of a novel anti-epileptic drug in healthy volunteers

Daniel Jonker The pharmacokinetics of the once-daily human glucagon-like peptide-1 analogue, liraglutide, across 5 trials in healthy subjects and type 2 diabetics after single and multiple dosing

Catherijne Knibbe Predictive Value of Allometric Scaling for Estimation of Propofol Clearance in Neonates, Infants and Adolescents

Elke Krekels Development AND External validation of a model for Glucuronidation in children below 3 years of age using morphine as a model drug; towards a novel dosing paradigm.

Glynn Morrish Using Body Composition Metrics to Predict Exposure Between Japanese and Caucasian Populations

FLORA MUSUAMBA-TSHINANU Limited sampling formulas and bayesian estimation for mycophenolic acid 12 hours Area Under the concentration-time Curve prediction in Stable renal transplant recipients co-medicated with cyclosporine or sirolimus

Rogier Press Optimizing Calcineurin Inhibitor Exposure In De Novo Kidney Transplant Recipients

Jean Smeets A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function

Tamara van Steeg Assessment of the use of complex baseline models in preclinical safety screening: Application of the van der Pol oscillator model to describe heart rate effects in rats

Johan Wallin Population pharmacokinetics of tacrolimus in paediatric bone marrow transplant recipients

Susan Willavize Using M&S to Shorten the Repeating Cycle of the Early Drug Development Process: A Case Study

Susan Willavize Dose Selection for Combination Drug Products

  1   2   3   4   5   6   7   8   9   ...   34


Poster abstracts page 2008 meeting Marseille, France iconAbstracts of Talks for the 2008 kymaa annual Meeting

Poster abstracts page 2008 meeting Marseille, France iconScroll further down the page. Poster/display projects Animals

Poster abstracts page 2008 meeting Marseille, France iconSpring Meeting – May 23-25, 2001 Book of Abstracts – Posters and Presentations

Poster abstracts page 2008 meeting Marseille, France iconFlorida Entomological Society, Eighty-fifth Annual Meeting, July 28-31, 2002, Abstracts of Pioneer Lecture, talks and posters, and author list

Poster abstracts page 2008 meeting Marseille, France iconAbstracts of the papers presented at the Second Satellite Meeting of the International Union of Pharmacology Teaching Section Asilomar Conference Center, Pacific Grove (CA), usa

Poster abstracts page 2008 meeting Marseille, France icon2/9/2012 Minutes of Anderson County Board of Education Regular Meeting Page No

Poster abstracts page 2008 meeting Marseille, France iconPersonal information born: 24 October 1958, Bosguerard de Marcouville, France Citizenships: France, usa (2005) education

Poster abstracts page 2008 meeting Marseille, France iconC civil engineering: page 110 community education: page 116 computing – applied: page 122 computing – e-commerce: page 128 D

Poster abstracts page 2008 meeting Marseille, France iconAuteur du document : Ian Eschstruth, étudiant en sociologie dernière mise à jour : 15/09/2008
«//») et les changements de page par «/p. Xx/», où XX est le numéro de la nouvelle page (par exemple : «/p. 25/»)
Poster abstracts page 2008 meeting Marseille, France icon[There seems to be a page before page one which has a descendant chart on it the only part that copied on page 1 reads as follows:]

Разместите кнопку на своём сайте:

База данных защищена авторским правом © 2014
обратиться к администрации
Главная страница